Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen is a promising medical technology company that offers diagnostic testing products under its AVISE brand for rheumatic and autoimmune diseases. Despite the company beating revenue expectations and showing positive volume and ASP growth, they have chosen to maintain their revenue guide for 2026, which may indicate conservative estimates. However, with an expanding sales force and new biomarker launches, Exagen is poised to dominate a market with significant need and limited competition, positioning them well for long-term growth potential.

Bears say

Exagen is facing several risks that could negatively impact its financial performance and valuation. These include potential challenges with commercial execution, reimbursement issues, payor concentration risks, and single product concentration risk. Additionally, the company operates as a small-cap company and may face difficulties accessing capital and becoming profitable. Other factors that could affect its outlook include competition, management execution, and regulatory risks related to its products.

Exagen Inc (XGN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.